Baipsis announced that the company plans to invest 150 million yuan with its own capital to jointly establish the Suzhou Sugaoxin Rongsheng Baipu Venture Capital Partnership with professional investment institutions, subscribe for 30% of its share and become a limited partner. The partnership has pledged a total investment of 500 million yuan, and no more than 800 million yuan after the subsequent fundraising is completed. It mainly invests in shares in unlisted companies in the fields of upstream life science tools and services, biomedicine, medical devices, biomantry, etc., and will last for 8 years. This investment is within the management's approval authority. It does not constitute a related transaction or major asset restructuring, and the partnership is not included in the scope of the company's consolidated statements.

Baipsis announced that the company plans to invest 150 million yuan with its own capital to jointly establish the Suzhou Sugaoxin Rongsheng Baipu Venture Capital Partnership with professional investment institutions, subscribe for 30% of its share and become a limited partner. The partnership has pledged a total investment of 500 million yuan, and no more than 800 million yuan after the subsequent fundraising is completed. It mainly invests in shares in unlisted companies in the fields of upstream life science tools and services, biomedicine, medical devices, biomantry, etc., and will last for 8 years. This investment is within the management's approval authority. It does not constitute a related transaction or major asset restructuring, and the partnership is not included in the scope of the company's consolidated statements.